The global market for long oligo pool synthesis for capture is experiencing significant growth, driven by advancements in genomic research, precision medicine, targeted sequencing, and clinical diagnostics. According to a recent report added to ResearchAndMarkets.com’s offerings, the market is expected to grow from $1.73 billion in 2025 to $1.97 billion in 2026, with a compound annual growth rate (CAGR) of 13.7%.
This market expansion is fueled by the increasing adoption of next-generation sequencing technologies, a rising demand for targeted sequencing solutions, and continued investment in cancer genomics research. The use of gene panel testing and advancements in array-based synthesis technologies have further strengthened the demand for scalable, accurate, and high-throughput capture solutions in both research and clinical settings.
Looking ahead, the market is projected to reach $3.31 billion by 2030, expanding at a CAGR of 13.9% from 2026. Key drivers of this growth include the rising demand for precision oncology, the integration of artificial intelligence in probe design, increased investment in synthetic biology, and the expansion of clinical genomic diagnostics. Additionally, there is a growing need for scalable multiplexed enrichment methods.
Several trends are shaping the long oligo pool synthesis market. These include the adoption of high-plex target enrichment panels, increased demand for custom capture probe libraries, and the use of automated probe design platforms. The expansion of CRISPR screening applications and a focus on cost-effective, high-throughput oligonucleotide synthesis are also notable trends. These developments are enhancing workflow efficiency and enabling more complex genomic analyses.
Precision medicine is a major growth driver for the market. The expanding use of genomic sequencing is facilitating more personalized approaches to disease diagnosis, treatment selection, biomarker identification, and patient stratification. Long oligo pool synthesis supports these applications by providing accurate genomic enrichment and customized probe design for targeted sequencing in both clinical and research environments.
Industry data underscores the increasing adoption of personalized treatments. The Personalized Medicine Coalition reports that the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, up from six approvals in 2022. Of these, seven were oncology drugs, while three addressed other diseases and conditions. This trend highlights the growing role of genomics in developing targeted therapies, which is expected to drive demand for advanced capture technologies.
Strategic partnerships are also playing a crucial role in the market. For instance, in January 2023, Twist Bioscience Corporation partnered with Centogene N.V. to introduce three next-generation sequencing target enrichment panels for rare disease and hereditary cancer research and diagnostics. These panels, curated using CENTOGENE’s Biodatabank of nearly 700,000 diverse patients, were synthesized by Twist Bioscience to support precise variant detection.
The prevalence and identification of genetic disorders are further contributing to market growth. Improvements in genetic screening and medical diagnostics are enabling healthcare professionals to detect more disease-associated mutations and genetic variants. Capture-based oligo synthesis facilitates precise targeting and enrichment of specific genomic regions, supporting accurate diagnosis, personalized treatment strategies, and targeted therapeutic development.
Data from the Cystic Fibrosis Trust illustrates this growing diagnostic and clinical need. The number of individuals living with cystic fibrosis in the United Kingdom increased from 11,148 in 2022 to 11,318 in 2023. As genetic testing becomes more integrated into healthcare systems, demand for reliable targeted sequencing and enrichment technologies is expected to rise.
Geographically, North America was the largest region in the long oligo pool synthesis for capture market in 2025, while Asia-Pacific is projected to be the fastest-growing region during the forecast period. The regions covered include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries included in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
The report categorizes the market by product type, synthesis method, application, and end-users. It covers custom capture probe libraries, pre-designed capture panels, capture reagent kits, amplification and enrichment reagents, and design software and analytical tools. Applications include targeted sequencing, gene synthesis, CRISPR screening, synthetic biology, and more.
Footnotes:
- The market is projected to grow from $1.73 billion in 2025 to $1.97 billion in 2026. Source.
- The market is expected to reach $3.31 billion by 2030. Source.
- The FDA approved 16 new personalized treatments in 2023. Source.
- Twist Bioscience partnered with Centogene N.V. in January 2023. Source.
Featured Image: Megapixl @ ARTFULLY-79
